TFF Pharmaceuticals Provided An Update From Its Ongoing Phase 2 Trial Of Tacrolimus Inhalation Powder For The Prevention Of Lung Transplant Rejection
Portfolio Pulse from Benzinga Newsdesk
TFF Pharmaceuticals has provided an update on its ongoing Phase 2 trial of Tacrolimus Inhalation Powder for preventing lung transplant rejection. Patient enrollment has accelerated, with 10 patients now enrolled. All 6 patients who completed the 12-week treatment have chosen to continue in the safety extension phase. The treatment has shown reduced variability in systemic exposure to Tacrolimus, potentially lowering the risk of acute rejection and systemic toxicities.
May 15, 2024 | 11:14 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TFF Pharmaceuticals' Phase 2 trial of Tacrolimus Inhalation Powder shows promising results with accelerated patient enrollment and reduced systemic exposure variability, potentially lowering the risk of acute rejection and systemic toxicities.
The accelerated patient enrollment and positive feedback from patients who completed the 12-week treatment indicate strong interest and potential efficacy of the treatment. Reduced variability in systemic exposure to Tacrolimus is a significant positive, as it could lower the risk of acute rejection and systemic toxicities, making the treatment more appealing.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100